At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 114 enrolled
Drug / intervention
Tirzepatide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI
In Brief
A Phase 1 clinical trial evaluating Tirzepatide, Placebo, and 1 other intervention for Obesity and Overweight. Completed, enrolled 114 participants across 3 sites.
Detailed Summary
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionDec 2022
TodayJul 2026
First PostedMar 17, 2020
Enrollment StartAug 24, 2020
Primary CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.3 years ago
Interventions
Tirzepatidedrug
Administered SC.
Placebodrug
Administered SC.
Liraglutidedrug
Administered SC.